Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Virology Journal

Fig. 1

From: Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status

Fig. 1

Detection of NY-ESO-1-specific antibodies in the plasma of HTLV-1-infected individuals with different clinical status Plasma anti-NY-ESO-1 antibody was detectable in 13.7% (7/51) of ACs, 29.2% (38/130) of patients with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP), and 18.9% (10/53) of patients with ATL. No humoral response against NY-ESO-1 was detected in 22 healthy uninfected controls (NCs). The plasma levels of anti-NY-ESO-1 was significantly higher in patients with HAM/TSP than in patients with ATL and ACs. NY-ESO-1 signals were evaluated by calculating the difference in absorbance values between the wells containing NY-ESO-1 and the wells containing PBS. Broken lines indicate the cut-off values (mean + 3 standard deviations of the control samples)

Back to article page